Clinical Trial Update: Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating R-FND chemotherapy plus Zevalin for high-risk follicular lymphoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Lymphoma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Fludarabine (Fludarabine)
• Mitoxantrone (mitoxantrone)
• R-FND
• Rituximab (rituximab)
• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2022-04-22